Venturi Wealth Management LLC Acquires 373 Shares of Cencora, Inc. (NYSE:COR)

Venturi Wealth Management LLC raised its position in Cencora, Inc. (NYSE:COR) by 8.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,820 shares of the company’s stock after acquiring an additional 373 shares during the period. Venturi Wealth Management LLC’s holdings in Cencora were worth $1,083,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Citizens & Northern Corp boosted its stake in Cencora by 3.0% in the fourth quarter. Citizens & Northern Corp now owns 7,354 shares of the company’s stock valued at $1,652,000 after acquiring an additional 212 shares in the last quarter. CIBC Asset Management Inc boosted its stake in Cencora by 3.3% in the fourth quarter. CIBC Asset Management Inc now owns 40,542 shares of the company’s stock valued at $9,101,000 after acquiring an additional 1,305 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in Cencora in the fourth quarter valued at approximately $221,000. Principal Financial Group Inc. boosted its stake in Cencora by 3.8% in the fourth quarter. Principal Financial Group Inc. now owns 318,401 shares of the company’s stock valued at $71,538,000 after acquiring an additional 11,675 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in Cencora in the fourth quarter valued at approximately $63,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

NYSE:COR opened at $241.37 on Wednesday. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. The firm has a market cap of $46.65 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 1.49 and a beta of 0.49. The firm’s fifty day moving average is $238.75 and its two-hundred day moving average is $237.41.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts expect that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s payout ratio is 31.29%.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on COR shares. Evercore ISI raised their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Robert W. Baird boosted their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.